Search results
Results from the WOW.Com Content Network
A glomus tumor (also known as a "solitary glomus tumor" [1]) is a rare neoplasm arising from the glomus body and mainly found under the nail, on the fingertip or in the foot. [2]: 670 They account for less than 2% of all soft tissue tumors. [3] The majority of glomus tumors are benign, but they can also show malignant features. [4]
Glomangiosarcoma is a low grade [1] tumor of the soft tissue. They rarely metastasize, [2] but metastases are possible. [3] It is also known as malignant glomus tumor. [4] Positive staining for vimentin has been reported. [5]
Cancer Treatment Centers of America (CTCA) was founded in 1988 by Richard J. Stephenson following the death of his mother, Mary Brown Stephenson, who died from lung cancer. [3] Stephenson purchased the American International Hospital in Zion, Illinois , in 1988 and expanded the hospital to include a radiation center, the Mary Brown Stephenson ...
Glomus tympanicum and Glomus jugulare, also known as jugulotympanic paraganglioma: Both commonly present as a middle ear mass resulting in tinnitus (in 80%) and hearing loss (in 60%). The cranial nerves of the jugular foramen may be compressed, resulting swallowing difficulty, or ipsilateral weakness of the upper trapezius and ...
A glomectomy is an excision of a glomus body or a glomus cell, usually in the case of a glomus tumor. This operation was formerly performed for the treatment of severe, chronic asthma, [1] but has since been abandoned for this purpose due to its lack of efficacy. [2] [3]
Treatment options for soft-tissue sarcomas include surgery, radiotherapy, chemotherapy, and targeted drug therapy. [3] Surgery is the most common treatment for soft-tissue sarcomas, and usually the only way to achieve a cure. The tumor is removed leaving a safe margin of surrounding healthy tissue to decrease the chances of its recurrence.
Hildreth's sign is a physical examination technique useful in differentiating glomus tumors and hemangiopericytomas from other masses with a similar appearance. It was first described by DH Hildreth, in 1970.
The alliance brings the renowned cancer center's access to research, clinical trials, and comprehensive treatment to leukemia, lymphoma and multiple myeloma patients. [25] In August 2020, Moffitt named Patrick Hwu, a tumor immunologist with 33 years of oncology experience, its new president and CEO. [26]